Dizal Pharmaceuticals
Clinical trials sponsored by Dizal Pharmaceuticals, explained in plain language.
-
New pill takes on chemo for rare lung cancer mutation
Disease control OngoingThis study compares a new targeted therapy pill (DZD9008) to standard chemotherapy in about 320 people with advanced non-small cell lung cancer that has a specific EGFR exon 20 insertion mutation. Participants are randomly assigned to receive either the pill or chemo. The main go…
Phase: PHASE3 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:37 UTC
-
New hope for lung cancer patients with Hard-to-Treat mutations
Disease control OngoingThis study tests a new drug called DZD9008 (sunvozertinib) in people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes and has stopped responding to other treatments. The goal is to check the drug's safety, side effects, and how well it …
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:35 UTC
-
New hope for Hard-to-Treat blood cancer: experimental drug shows promise
Disease control OngoingThis study tests an experimental drug called DZD8586 in about 59 adults with diffuse large B-cell lymphoma that has returned or stopped responding to prior treatment. The goal is to see if the drug can shrink tumors and to understand its side effects. Participants take the drug a…
Phase: PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 10:33 UTC